Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04773782




Registration number
NCT04773782
Ethics application status
Date submitted
9/02/2021
Date registered
26/02/2021
Date last updated
15/06/2023

Titles & IDs
Public title
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Scientific title
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Secondary ID [1] 0 0
BLU-285-3101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumor, Unspecified, Child 0 0
Relapsed Solid Neoplasm 0 0
CNS Tumor 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - avapritinib

Experimental: avapritinib - Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.


Treatment: Drugs: avapritinib
oral administration
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Determination of recommended Part 2 dose (Part 1)
Timepoint [1] 0 0
up to 8 months
Primary outcome [2] 0 0
Objective Response Rate (Part 2)
Timepoint [2] 0 0
up to 36 months
Primary outcome [3] 0 0
Rate and severity of adverse events (Part 1)
Timepoint [3] 0 0
up to 8 months
Secondary outcome [1] 0 0
Objective Response Rate (Part 1 and Part 2)
Timepoint [1] 0 0
up to 42 months
Secondary outcome [2] 0 0
Rate and severity of adverse events (Part 1 and Part 2)
Timepoint [2] 0 0
up to 42 months
Secondary outcome [3] 0 0
Palatability assessments as measured by the 5-point Hedonic scale (Part 1 and Part 2)
Timepoint [3] 0 0
up to 42 months
Secondary outcome [4] 0 0
Duration of Response (Part 1 and Part 2)
Timepoint [4] 0 0
up to 42 months
Secondary outcome [5] 0 0
Progression-free survival (Part 1 and Part 2)
Timepoint [5] 0 0
up to 42 months
Secondary outcome [6] 0 0
Disease control rate (Part 1 and Part 2)
Timepoint [6] 0 0
up to 42 months
Secondary outcome [7] 0 0
Time to response (Part 1 and Part 2)
Timepoint [7] 0 0
up to 42 months
Secondary outcome [8] 0 0
Cmax (Part 1 and Part 2)
Timepoint [8] 0 0
up to 36 months
Secondary outcome [9] 0 0
AUC(0-24) (Part 1 and Part 2)
Timepoint [9] 0 0
up to 36 months
Secondary outcome [10] 0 0
Tmax (Part 1)
Timepoint [10] 0 0
up to 36 months
Secondary outcome [11] 0 0
T 1/2 (Part 1)
Timepoint [11] 0 0
up to 36 months
Secondary outcome [12] 0 0
Ctrough (Part 2)
Timepoint [12] 0 0
up to 36 months
Secondary outcome [13] 0 0
Change from baseline in levels of KIT and PDGFRA mutant allele fractions in peripheral blood (Part 1 and Part 2)
Timepoint [13] 0 0
up to 42 months

Eligibility
Key inclusion criteria
Inclusion Criteria

1. Participant must be 2 to < 18 years of age at the time of signing the informed
consent.

2. Diagnosis

1. Participant has confirmed diagnosis of R/R solid tumor, including CNS tumors,
with a mutation (including non-synonymous point mutations, insertions, and
deletions) in PDGFRA and/or KIT (confirmed by local mutational testing of tumor
sample) that has progressed despite standard therapy and no alternative treatment
option is available. Participant with R/R solid tumors with only PDGFRA and/or
KIT amplifications may be included with approval from the Sponsor.

OR

2. Participant has confirmed diagnosis of DMG-H3K27a (confirmed by local testing of
tumor sample) that has failed standard therapy or for which no standard therapy
that may convey clinical benefit exists, as judged by the investigator.

3. Participants with CNS disease should be on a stable (= 10% change) or decreasing dose
of corticosteroids for at least 7 days prior to first dose of avapritinib, with no
plans for dose escalation.

4. Disease extent: a. Part 1: All participants must have at least 1 measurable lesion as
defined by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) (for CNS
tumors). If radiation therapy has been administered, at least 1 measurable lesion must
not have been irradiated, or must have clearly progressed since being irradiated as
per RANO and must be = 12 weeks from radiation to any target lesion.

b. Part 2: All participants must have at least 1 measurable lesion as defined by
RECIST v1.1 or RANO (for CNS tumors). For Participants with DMG-H3K27a or PDGFRA
and/or KIT mutant/amplified solid tumors, including CNS tumors that have progressed
despite prior therapy, who have received radiation therapy, at least 1 measurable
lesion must not have been irradiated, or must have clearly progressed since being
irradiated as per RANO and must be = 12 weeks from radiation to any target lesion. For
up to 5 Participants with newly diagnosed DMG-H3K27a where there is no standard
therapy that may convey clinical benefit exists as judged by the investigator,
progression of disease of a measurable lesion after irradiation is not required.

5. A Lansky (< 16 years of age) or Karnofsky (= 16 years of age) score of at least 50. If
the Participant is unable to walk due to paralysis, but is mobile in a wheelchair, the
participant is considered ambulatory for the purpose of assessing their performance
status.

6. Participant agrees to utilize contraception consistent with local regulations.

- Male participants: Are vasectomized, or agree to use condoms, as defined in
Section 5.4.2, from the start of Screening until 6 weeks after the last dose of
study treatment, or practice true abstinence (when this is in line with the
preferred and usual lifestyle of the Participant, see Section 5.4.2), or have a
female partner who is NOT of childbearing potential.

- Female participants: Agree to use effective contraception, as defined in Section
5.4.2, from the start of Screening until 6 weeks after the last dose of study
treatment and have a male partner who uses a condom, or practice true abstinence
(when this is in line with the preferred and usual lifestyle of the Participant),
or have a male partner who is vasectomized with confirmed azoospermia.

7. Participant can give written informed consent/assent before any study-specific
Screening procedures (if feasible). Parental/legal guardian consent will be determined
by local, regional, and/or national guidelines.
Minimum age
2 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

1. Participant has any of the following within 14 days before the first dose of study
treatment:

1. Platelet count < 75 × 10^9/L (< 100 × 10^9/L if a CNS tumor) with no platelet
transfusion within 14 days prior to the measurement.

2. Absolute neutrophil count (ANC) < 1.0 × 10^9/L.

3. Hemoglobin < 8.0 g/dL with no RBC transfusion = 7 days prior to the measurement.

4. AST or ALT > 3 × the ULN for age; except in Participants with tumor involvement
of the liver who must not have AST and ALT > 5 × ULN for age.

5. Total bilirubin > 1.5 × ULN for age; and in presence of Gilbert's syndrome, total
bilirubin > 3 × ULN or direct bilirubin > 1.5 × ULN.

6. Serum creatinine > 1.5 × ULN for age.

7. International normalized ratio or prothrombin time (PT) > ULN (> 1.5 × ULN if on
prophylactic reversible anticoagulants).

2. Participant has a QTcF > 470 msec. Participant has a familial or personal history of
prolonged QT syndrome or Torsades de pointes.

3. Participant has clinically significant, uncontrolled cardiovascular disease including
congestive heart failure Grade III or IV according to the New York Heart Association
classification; myocardial infarction or unstable angina within the previous 6 months,
uncontrolled hypertension (> 95th percentile for age), or clinically significant,
uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation
(eg, Type II second-degree heart block or third-degree heart block).

4. Participant received the following systemic antineoplastic therapies:

1. Temozolomide within 4 weeks prior to the first dose of study drug

2. Nitrosurea within 6 weeks prior to the first dose of study drug

3. Any other systemic antineoplastic therapy (including experimental therapy) within
5 half-lives or 28 days prior to the first dose of study drug, whichever is
shorter.

4. Focal external beam radiotherapy, including stereotactic radiosurgery, within 6
weeks prior to the first dose of avapritinib to either target or nontarget
lesions. Systemic radiopharmaceuticals, including nonstereotactic radiosurgery,
within 2 weeks of the first dose of avapritinib (within 6 weeks for Participants
with CNS tumors). Craniospinal irradiation within 6 weeks prior to the first dose
of avapritinib.

5. All AEs related to other antineoplastic therapies (eg, systemic antineoplastics,
radiotherapy) must have resolved to Grade = 1 (Grade = 2 for peripheral
neuropathy and/or ototoxicity) prior to the first dose of avapritinib.

5. Participant has previously received treatment with avapritinib.

6. Participant received autologous stem cell transplant following myeloablative therapy
or chimeric antigen receptor T cell therapy within 3 months prior to the first dose of
avapritinib or prior allogeneic stem cell transplant within 1 year and no evidence of
Grade 1 or greater graft-versus-host disease and no immunosuppressants for
graft-versus-host disease (steroids for primary malignancy being permitted).
Participants who received stem cell reinfusion following nonmyeloablative therapy are
eligible once they meet the peripheral blood count criteria in Exclusion Criterion #1.

7. Participant requires ongoing treatment or has received treatment within 28 days before
the start of avapritinib administration with drugs or foods that are strong CYP3A
inhibitors or inducers.

8. Participant has had a major surgical procedure within 14 days of the first dose of
study treatment (procedures such as central venous catheter placement, tumor needle
biopsy, and feeding tube placement are not considered major surgical procedures).

9. Participant has a history of another primary malignancy that has been diagnosed or
required therapy within 3 years before the first dose of avapritinib. The following
prior malignancies are not exclusionary: completely resected basal cell and squamous
cell skin cancer, curatively treated localized prostate cancer, and completely
resected carcinoma in situ of any site.

10. Female subjects of childbearing potential who are unwilling, if not postmenopausal or
surgically sterile, to abstain from sexual intercourse or employ highly effective
contraception from the time of informed consent and for at least 6 weeks after the
last dose of study treatment. Male subjects who are unwilling, if not surgically
sterile, to abstain from sexual intercourse or employ highly effective contraception
from the time of informed consent and for at least 6 weeks after the last dose of
study treatment.

11. Participant is pregnant, as documented by a serum ß-hCG pregnancy test consistent with
pregnancy obtained at Screening and within 72 hours before the first dose of study
treatment. Participants with ß-hCG values that are within the range for pregnancy but
are not pregnant (false-positives) may be enrolled with written consent of the Sponsor
after pregnancy has been ruled out. Female subjects of nonchildbearing potential
(premenarchal, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) do
not require a serum ß-hCG test.

12. Participant is breastfeeding.

13. Participant has prior or ongoing clinically significant illness, medical condition,
surgical history, physical finding, or laboratory abnormality that, in the
Investigator's opinion, could affect the safety of the Participant; alter the
absorption, distribution, metabolism, or excretion of the study drug; or impair the
assessment of study results.

14. History of thrombosis requiring treatment within the past 6 months. This exclusion
does not apply to catheter-related thrombosis if the catheter has been removed and did
not require any other treatment in the previous 3 months.

15. Participants who require anticoagulants, with the exception of stable doses of
prophylactic reversible anticoagulants.

16. Participants who are unable to swallow tablets (in Part 1) or minitablets (in Part 2)
within the sprinkle capsules.

17. Participants with a known risk of intracranial bleeding, such as a brain aneurysm that
has not been removed or repaired, or a history of intracranial bleeding within the
past year, or radiographic evidence of hemorrhage on Screening MRI. Exceptions are:
Participants with primary CNS tumors (provided they have not had CNS bleeding within 2
weeks of the first dose of avapritinib) or Participants with punctate hemorrhages < 3
mm.

18. History of a seizure disorder that is not well controlled on current antiepileptic
medications.

19. Participant is unwilling or unable to comply with scheduled visits, treatment
administration plan, laboratory tests, or other study procedures and study
restrictions.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/04/2025
Actual
Sample size
Target
37
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Sydney Children's Hospital, Kids Cancer Center - Sydney
Recruitment hospital [2] 0 0
Royal Children's Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2031 - Sydney
Recruitment postcode(s) [2] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
Austria
State/province [15] 0 0
Vienna
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario
Country [17] 0 0
France
State/province [17] 0 0
Villejuif
Country [18] 0 0
Germany
State/province [18] 0 0
Lower Saxony
Country [19] 0 0
Germany
State/province [19] 0 0
Heidelberg
Country [20] 0 0
Italy
State/province [20] 0 0
Milan
Country [21] 0 0
Korea, Republic of
State/province [21] 0 0
Seoul
Country [22] 0 0
United Kingdom
State/province [22] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Blueprint Medicines Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18
years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous
system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point
mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available
curative treatment options. This is a single-arm trial in which all participants will receive
avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and
initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04773782
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Blueprint Medicines
Address 0 0
Country 0 0
Phone 0 0
617-714-6707
Fax 0 0
Email 0 0
medinfo@blueprintmedicines.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04773782